Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Discovery of counterfeit hepatitis C drug is another example of why importation is bad for patients

By Nicole Longo  |    February 13, 2017
The manufacturing and trafficking of counterfeit drugs is not just a U.S. concern but a growing threat globally. Governments around the world are working together to try to prevent these fake...   Read More

Focusing on patients and progress on World Hepatitis Day

By Hannah Mooney  |    July 28, 2016
World Hepatitis Day is a unique opportunity to take stock of the recent advancements in new treatments and cures to combat versions of hepatitis. Founded by the World Hepatitis Alliance, World...   Read More

New report celebrates a decade of progress in chronic diseases

By Holly Campbell  |    February 25, 2016
In the last 10 years, incredible progress has been made by the biopharmaceutical industry in the treatment of chronic diseases. With about half of all Americans, or 117 million people, living with...   Read More

Local Impact: Hepatitis C and Medicaid spending

By Priscilla VanderVeer  |    December 22, 2015
There has been a lot of discussion about the cost of new hepatitis C treatments to state Medicaid programs. What has not been addressed, however, is how those costs stack up against older, less...   Read More

Critics proven wrong again on medicine spending

By Holly Campbell  |    December 9, 2015
Recent comments from pharmacy benefit managers and insurers disprove – once again – the fallacious claims previously made about spending on new innovative medicines. Over the past year, payers...   Read More

Medicare Monday: New hepatitis C treatments in Medicare

By Ashley Flint  |    November 2, 2015
America’s innovative biopharmaceutical companies are committed to researching and developing treatments that help patients live longer, healthier lives. In recent years new treatments for...   Read More

ICYMI: New cholesterol-lowering medicines will not be “budget busters”

By Holly Campbell  |    October 8, 2015
In case you missed it, Express Scripts, the nation’s largest pharmacy benefit manager, announced that it will include two new cholesterol-lowering medicines, called PCSK9 inhibitors, on its...   Read More

Week in Review: The Latest from PhRMA

By Priscilla VanderVeer  |    September 25, 2015
Protecting Innovation: The current marketplace for prescription medicines helps keep spending in check and continued innovation for patients possible. A recent proposal by Presidential Candidate...   Read More

New report: Eliminating hepatitis C today could reduce future U.S. health care spending by $115 billion over the next decade

By Holly Campbell  |    September 24, 2015
Costs and Consequences is a blog series examining the health care burden of not treating diseases. Too often, the rhetoric focuses solely on the cost of medicines and disregards the adverse...   Read More

ICYMI – New York Times Editorial Board: Hepatitis C medicines a high value for patients and health care system

By Tina Stow  |    September 4, 2015
In a September 2 editorial, The New York Times Editorial Board concludes that “competitive market forces and hard-nosed bargaining” make “tremendously effective” new hepatitis C medicines not just...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates